Compliance: Vicodin’s new DEA status could impact your NPPs, patients and practice flow

Why This Topic Matters

It helps practices understand a federal drug-scheduling change that can affect prescribing workflows, state-specific privileges for non-physician practitioners, and day-to-day prescription processing.

Article Sections

1. DEA rescheduling overview

   Introduces the federal scheduling change and places it in the context of controlled-substance prescribing for pain medications. It also frames the broader compliance implications for practice teams.

2. NPPs in 18 states, 1 territory impacted

   Discusses how the scheduling change may affect non-physician practitioner prescribing authority across selected states and territories. It highlights the need to review state scope-of-practice rules and related prescribing limits.

3. Review the Schedule II drill with staff

   Summarizes general office workflow considerations for handling controlled-substance prescriptions after the rescheduling. The section emphasizes staff awareness, pharmacy coordination, and other administrative handling issues.

4. Official resources

   Lists reference materials and official sources related to the scheduling change and prescriptive authority information.